Efficacy and safety of necitumumab and pembrolizumab combination therapy in advanced non-small-cell lung cancer with ≥50% PD-L1 expression: A nonrandomized phase II trial.

Horiike A, Wakui H, Sugawara S, Minegishi Y, Tasaka S, Kusumoto S, Sakatani T, Suzuki H, Hosomi Y, Tambo Y, Shimokawa T, Ishida H, Miyauchi E, Naoki K, Fukuhara T, Mura E, Tsurui T, Suzuki R, Iriguchi N, Ishiguro T, Hirasawa Y, Manabe R, Shimokawa M, Ohkuma R, Ariizumi H, Kubota Y, Hamada K, Takenoshita S, Ryu K, Sambe T, Inoue E, Wada S, Yoshimura K, Sagara H, Kobayashi S, Tsunoda T

Open source

DOI: 10.1158/1078-0432.ccr-25-2751
Published: 2026 Jul 27
Container: Clinical cancer research : an official journal of the American Association for Cancer Research
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1158/1078-0432.ccr-25-2751,
  title = {Efficacy and safety of necitumumab and pembrolizumab combination therapy in advanced non-small-cell lung cancer with ≥50\% PD-L1 expression: A nonrandomized phase II trial.},
  author = {Horiike A and Wakui H and Sugawara S and Minegishi Y and Tasaka S and Kusumoto S and Sakatani T and Suzuki H and Hosomi Y and Tambo Y and Shimokawa T and Ishida H and Miyauchi E and Naoki K and Fukuhara T and Mura E and Tsurui T and Suzuki R and Iriguchi N and Ishiguro T and Hirasawa Y and Manabe R and Shimokawa M and Ohkuma R and Ariizumi H and Kubota Y and Hamada K and Takenoshita S and Ryu K and Sambe T and Inoue E and Wada S and Yoshimura K and Sagara H and Kobayashi S and Tsunoda T},
  year = {2026},
  journal = {Clinical cancer research : an official journal of the American Association for Cancer Research},
  doi = {10.1158/1078-0432.ccr-25-2751},
  url = {https://doi.org/10.1158/1078-0432.ccr-25-2751}
}

RIS

TY  - JOUR
TI  - Efficacy and safety of necitumumab and pembrolizumab combination therapy in advanced non-small-cell lung cancer with ≥50% PD-L1 expression: A nonrandomized phase II trial.
AU  - Horiike A
AU  - Wakui H
AU  - Sugawara S
AU  - Minegishi Y
AU  - Tasaka S
AU  - Kusumoto S
AU  - Sakatani T
AU  - Suzuki H
AU  - Hosomi Y
AU  - Tambo Y
AU  - Shimokawa T
AU  - Ishida H
AU  - Miyauchi E
AU  - Naoki K
AU  - Fukuhara T
AU  - Mura E
AU  - Tsurui T
AU  - Suzuki R
AU  - Iriguchi N
AU  - Ishiguro T
AU  - Hirasawa Y
AU  - Manabe R
AU  - Shimokawa M
AU  - Ohkuma R
AU  - Ariizumi H
AU  - Kubota Y
AU  - Hamada K
AU  - Takenoshita S
AU  - Ryu K
AU  - Sambe T
AU  - Inoue E
AU  - Wada S
AU  - Yoshimura K
AU  - Sagara H
AU  - Kobayashi S
AU  - Tsunoda T
PY  - 2026
JO  - Clinical cancer research : an official journal of the American Association for Cancer Research
DO  - 10.1158/1078-0432.ccr-25-2751
UR  - https://doi.org/10.1158/1078-0432.ccr-25-2751
ER  -

APA

A, H., H, W., S, S., Y, M., S, T., S, K., T, S., H, S., Y, H., Y, T., T, S., H, I., E, M., K, N., T, F., E, M., T, T., R, S., N, I., T, I., Y, H., R, M., M, S., R, O., H, A., Y, K., K, H., S, T., K, R., T, S., E, I., S, W., K, Y., H, S., S, K., & T, T. (2026). Efficacy and safety of necitumumab and pembrolizumab combination therapy in advanced non-small-cell lung cancer with ≥50% PD-L1 expression: A nonrandomized phase II trial.. Clinical cancer research : an official journal of the American Association for Cancer Research. https://doi.org/10.1158/1078-0432.ccr-25-2751

Source records

pubmed · retrieved 2026-09-27T08:21:07.421Z